GlassScriptPhysician profile
Amit H Masand
NPI 1568637825
$10,801.80
in general payments reported to CMS, 2019-2025
44 companies · $1,700 in 2025
The $1,700 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,742 · 2020: $742 · 2021: $1,658 · 2022: $1,752 · 2023: $1,478 · 2024: $1,729 · 2025: $1,700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,859 · Education: $48.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,858.57 |
| Education | $48.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,187.17 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,466.03 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $839.74 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $574.51 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Qol Medical, LLC | $450.11 | 2019-2025 | Sucraid, Sucraid |
| Vivus LLC | $399.19 | 2021-2025 | Qsymia, Pancreaze |
| Romark Laboratories, Lc | $387.25 | 2019-2020 | |
| Celgene Corporation | $278.34 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $273.11 | 2019-2024 | Zerbaxa, Dificid, Recarbrio |
| Regeneron Healthcare Solutions, INC. | $198.07 | 2022-2025 | Dupixent |
| Genzyme Corporation | $195.61 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $194.61 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $171.20 | 2024-2025 | Zenpep, Vowst |
| Phathom Pharmaceuticals, INC. | $164.01 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $153.07 | 2019-2020 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $152.72 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $150.61 | 2019-2023 | Linzess |
| Ardelyx, INC. | $150.39 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $145.21 | 2019-2023 | Clenpiq |
| Redhill Biopharma INC. | $117.09 | 2020-2022 | |
| Pfizer INC. | $116.08 | 2019-2025 | |
| Alfasigma USA, INC. | $102.93 | 2020 | |
| Intercept Pharmaceuticals, INC. | $90.85 | 2019-2023 | Ocaliva |
| Evoke Pharma, INC. | $82.91 | 2020-2023 | Gimoti |
| Fresenius Kabi USA, LLC | $68.31 | 2023-2024 | Idacio |
| Madrigal Pharmaceuticals | $64.41 | 2024-2025 | Resmetirom, Rezdiffra |
| Lilly USA, LLC | $56.84 | 2025 | Omvoh |
| Gilead Sciences, INC. | $55.84 | 2019-2023 | |
| Shionogi INC | $52.79 | 2019 | |
| Braintree Laboratories, INC. | $50.76 | 2021-2023 | Sutab |
| Abbott Laboratories | $49.86 | 2019 | |
| Celltrion USA INC. | $48.94 | 2024 | Zymfentra |
| Perspectum Diagnostics LTD | $48.36 | 2022 | |
| Ucb, INC. | $44.91 | 2019 | |
| Medtronic, INC. | $42.71 | 2022-2024 | Gi Genius |
| Ethicon US, LLC | $31.92 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $27.86 | 2022-2023 | |
| Paratek Pharmaceuticals, INC. | $26.87 | 2021 | |
| Amgen INC. | $20.30 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $19.15 | 2025 | Iqirvo |
| Novo Nordisk INC | $17.92 | 2025 | Wegovy |
| Organon LLC | $17.82 | 2023 | Hadlima, Renflexis |
| Endogastric Solutions, INC | $15.42 | 2024 | Esophyx |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$30,053.89 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Masand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.